The Spin Pharma editorial desk reports on biotech, AI, genomics, medtech, cancer research and longevity, linking every claim to primary research, trial records or regulators. Articles are reviewed by a human editor before publication.
Cancer FrontiersCancer is more than 100 diseases, and whether one can be cured depends on its type, its stage and the treatments that can reach it. Here is what doctors mean by cure, remission and “no evidence of disease.”
Cancer FrontiersTargeted drugs, checkpoint inhibitors, CAR-T cells and biomarker testing have joined surgery, radiation and chemotherapy. Each works differently, helps some patients dramatically and others not at all.
AI + MedicineIn breast screening, AI support has been tested in a randomized trial of more than 100,000 women and a real-world study of 460,000. The results are promising, but false alarms, overdiagnosis and deskilling still matter.
AI + MedicineAI reconstruction has nearly halved knee MRI scan times in clinical studies without losing diagnostic accuracy. But networks that fill in missing data can also invent or erase detail, so validation must be specific.
AI + MedicineAI now helps find drug targets, predict protein shapes and design molecules. But most drugs fail in clinical trials because they don't work well enough or are too toxic, and AI hasn't yet shown it can change that.
BreakthroughsKilling diseased cells in a dish is the easy part of drug development. This guide explains the evidence ladder, why most candidates fail, and seven questions to ask before believing a breakthrough headline.
Genome + CellsFrom the $3 billion Human Genome Project to routine sequencing, reading DNA has become easy. Here is what a genome can reveal today, and where uncertain variants, risk scores and missing context set hard limits.
Genome + CellsIn December 2023 the FDA approved Casgevy, the first CRISPR-based therapy, for sickle cell disease. Here is how gene editing, gene therapy and RNA medicines differ, and what that approval does and doesn't prove.
LongevitySome problems of ageing may start inside individual cells. This explainer tours senescence and mitochondria, from striking mouse results to small, mixed human trials, and explains why no therapy is yet approved to treat ageing.
LongevityLongevity claims are everywhere, but human evidence is thin. This field guide sorts the most popular anti-ageing ideas by what has been shown in animals, what has been tested in people, and what nobody knows yet.
BreakthroughsA positive Phase 1 result and a positive Phase 3 result sound similar but mean very different things. Here is what each stage of a clinical trial is designed to show, and what it cannot.
Companies + StocksMany biotech startups spend years building evidence rather than selling products. This map traces the stations most pass through, from licensing a discovery to the forks where companies partner, sell, go public or stop.